http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Minipig can Replace a Dog in Non-rodent Toxicity Study
Sang-Koo Lee,Youn-Sang Kweon,Chester D. Solis,Shin-Joung Rho,Tae-Ho Kim 한국실험동물학회 2007 Laboratory Animal Research Vol.23 No.3
This study was conducted to compare the difference of quantitative toxicity of a compound which has different metabolic pathways in minipig and beagle dog. Coumarin which has low toxic values in human and different metabolic pathways in these two animals was chosen as a test compound. In the single dose toxicity study conducted using minipig, maximum tolerable dose (MTD) of coumarin was determined to be 200 ㎎/㎏/day and liver was confirmed as a target organ. However, MTD value of coumarin in the dog study was 60-100 ㎎/㎏/day and target organs were liver and kidneys. Minipig which has similar metabolic pathway of coumarin with human showed similar acute toxicity when compared with previously published data. Although it is difficult to conclude without further toxicity studies, it was expected from this study that animals having similar metabolic pathways with human should be chosen during the toxicity studies of new chemicals to predict the accurate toxicity and target organs in the human.
Development of New Oral Administration Method in Minipig
Sang-Koo Lee,Youn-Sang Kweon,Chester D. Solis,Tae-Ho Kim 한국실험동물학회 2007 Laboratory Animal Research Vol.23 No.3
Pigs have increasingly become useful models for regulatory toxicity testing because of the similarities of their cardiovascular, renal and digestive systems to those of humans. The minipig, because of its size (adult weight of approximately 30-70 ㎏), is easier to handle and requires smaller amounts of test substances. This makes minipig as a suitable species for preclinical safety study and their seems to be no obvious regulatory barrier. Through this study, we could develop an easy and convenient oral administration method which did not induce any stress signs in minipigs during 4-week treatment period. We will introduce the details and want to be helpful to the other technicians conducting pharmacological and toxicological studies.
Single and 28-day Repeated Dose Toxicity Studies of Coumarin in the Minipig
Sang-Koo Le,Youn-Sang Kweon,Chester D Solis,Shin-Joung Rho,Tae-Ho Kim 한국실험동물학회 2008 Laboratory Animal Research Vol.24 No.3
The minipig is becoming increasingly used as a test animal both in pharmacological and toxicological studies of new drugs. Coumarin is a natural product which presents in foodstuffs and use in clinical medicine. However, coumarin shows marked toxicity in some species of animals and species differences in toxicity depend on metabolic activation of coumarin. Enzymatic process of coumarin metabolism in minipig is similar to that of human. This study was conducted to compare the toxicity data of coumarin in the minipig with other animal species and to confirm the usefulness of minipig in the regulatory toxicity studies. Single and 28 day repeated-dose toxicity studies of coumarin were conducted using minipigs. In the single dose toxicity study, maximum tolerated dose (MTD) value of coumarin was determined to be a 200 ㎎/㎏/day and liver was decided as a target organ. Based on the single dose toxicity study, twenty-eight day repeated dose study was conducted at dose levels of 0, 50, 100, and 200 ㎎/㎏/day. Middle and high dose minipigs showed clinical signs and pathological lesions in the liver and kidneys. Low dose group minipigs did not display any clinical signs and functional abnormalities considered to have relation with coumarin treatment, but showed significant increase of liver weight. From the above findings, no observable effect level (NOEL) of minipig was determined to be below 50 ㎎/㎏/day.
Development of a type II diabetic mellitus animal model using Micropig®
Myeong-Seop Lee,Hee-Jun Yang,Chester D. Solis,Ki-Duk Song,Soo-Hyeon Kim,Woon-Kyu Lee 한국실험동물학회 2012 Laboratory Animal Research Vol.28 No.3
Diabetes, which has shown an explosive increase in terms of its incidence, is regarded as a serious disease that must be overcome for the sake of human life. Among animal models used for testing of drug efficacy, the mini-pig model has shown a rapid upload due to its many similarities with human, particularly concerning the pharmacokinetics of compounds after subcutaneous administration, the structure and function of the gastrointestinal tract, the morphology of the pancreas, and overall metabolic status. Based on these various advantages, we sought to develop an animal model of type II diabetic mellitus using the Micro-pig, which differs from other miniature pigs. We used six male Micro-pigs for induction of a moderate insulin deficient model with nicotinamide (NIA)/streptozotocin (STZ) treatment and three animals for control. For evaluation of incidence of type II diabetes, we measured blood glucose level, and performed oral glucose tolerance test and immunohistochemistry on pancreatic tissue using insulin antibody. Compared to control animals, all animals treated with NIA/STZ showed high levels of glucose and low levels of insulin. In addition, we observed the partially destroyed beta cell population from tissue of the pancreas in treated animals. Based on these results, we report that the Micro-pig model developed in this study can be used for testing of the efficacy of therapeutic agents for treatment of Type 2 diabetic mellitus.
Development of osteoporosis animal model using micropigs
Sang-Woo Kim,Kyoung-Shim Kim,Chester D. Solis,Myeong-Seop Lee,Byung-Hwa Hyun 한국실험동물학회 2013 Laboratory Animal Research Vol.29 No.3
Osteoporosis is a known major health problem and a serious disease of the bone, there has been a great need to develop more and newer animal models for this disease. Among animal models used for testing drug efficacy, the minipig model has become useful and effective due to its close similarity with humans (validity), particularly with the pharmacokinetics of compounds via subcutaneous administration, the structure and function of the organs, the morphology of bone and the overall metabolic nature. Based on these advantages, we sought to develop a new animal model of osteoporosis using micropig, which differs from other miniature pigs in the genetic background. Female micropigs were used for the induction of a moderate osteoporosis model by bilateral ovariectomy (OVX) and compared with shamoperated animals. For osteoporosis evaluation, clinical biomarkers such as blood osteocalcin (OSC) and parathyroid hormone (PTH) levels were measured, as well as bone mineral density (BMD) using microcomputed tomography (micro-CT). Compared to sham, OVX animals have decreased blood OSC level, while the blood PTH level increased in blood sera. In addition, we observed the significantly decreased BMDs of tibia region in OVX animals. Based on these results, we report that the micropig model developed in this study can be used to develop a new and effective medical method for diagnosis and treatment of osteoporosis.